Ixazomib/Enleri in the treatment of multiple myeloma: Is it a chemotherapy drug or something else?

Ixazomib, trade name: Ixazomib (Ixazomib), is an oral anti-tumor drug that has attracted much attention in recent years, specifically targeting the treatment of multiple myeloma. However, unlike chemotherapy drugs in the traditional sense, it is actually a proteasome inhibitor. The proteasome, as a key component inside cells, is mainly responsible for the removal of waste or damaged proteins. Ixazomib can effectively disrupt the growth rhythm and survival mechanism of cancer cells by precisely inhibiting the activity of the proteasome.

When treating multiple myeloma, ixazomib does not work alone, but often works together with drugs such as lenalidomide and dexamethasone to form a powerful combination treatment plan. This strategy not only significantly improves the therapeutic effect, but also effectively solves the problem of drug resistance that a single drug may face. Studies have shown that patients treated with ixazomib combination therapy achieved impressive improvements in progression-free survival and overall survival.

It is worth mentioning that the oral administration method of ixazomib brings unprecedented convenience to patients. Compared with traditional intravenous chemotherapy, patients do not need to go to the hospital frequently. They can easily receive treatment at home by taking medicine on time. This is undoubtedly a great boon for patients who are elderly, frail or have limited mobility.

Of course, any medication may inevitably be accompanied by some side effects. Although ixazomib is relatively mild, it may still cause mild discomfort such as nausea, fatigue, and rash, as well as certain effects on the blood system, such as a decrease in white blood cells or platelets. Therefore, during the treatment process, the doctor will pay close attention to the patient's physical condition and flexibly adjust the treatment plan according to the actual situation.